Cagrilintide
Long-acting amylin analogue (AM833). Promotes satiety and slows gastric emptying. Once-weekly injection. Often combined with semaglutide.
What is Cagrilintide?
Cagrilintide (AM833) is a long-acting synthetic amylin analogue (DACRA). It acts on amylin and calcitonin receptors: promotes satiety and slows gastric emptying. Half-life is about 7 days, so it is given once weekly.
Injection Protocol
Doses in clinical trials: 0.16 mg to 4.5 mg once weekly subcutaneously.
Titration: start with a low dose (e.g. 0.3–0.6 mg), increase every 2–4 weeks as tolerated. Can be combined with semaglutide for greater effect.
Injection sites: abdomen, thigh, or upper arm. Rotate weekly.
Vial Reconstitution
For a 2 mg vial + 1 ml bacteriostatic water: 2 mg/ml → 0.5 mg = 0.25 ml = 25 units (U-100). Adjust for your vial size.
Storage
Unreconstituted vial: refrigerate (+2°C to +8°C). After reconstitution: refrigerate, use within 28 days. Do not freeze.
Important Warnings
- Drug is in clinical development; not yet approved for general use.
- Side effects: nausea, dyspepsia, vomiting (mostly mild to moderate).
- Do not use if you have pancreatitis or medullary thyroid cancer.
Peptides are often supplied as a dry powder and must be reconstituted with bacteriostatic water. After reconstitution, many manufacturers recommend using the solution within about 2 weeks, because peptide stability may gradually decrease over time. Marking a "new vial" helps track when a vial was first reconstituted and how long it has been in use.
Not sure if therapy is working?
Take a short effectiveness assessment — we'll check your food noise level and interpret the result.
Take assessmentOnce signed in, you can record injections and keep your injection history.
Sign inRapid weight loss burns muscle. Avoid Ozempic face by tracking your protein intake.
Check Protein Norm